BioNTech’s Oncology Ambitions Advance with Promising Breast Cancer Trial Data

BioNTech SE has achieved a significant milestone in its oncology pipeline, with a novel breast cancer therapy demonstrating superior results in a pivotal late-stage trial. The development marks a crucial step for the Mainz-based company as it seeks to diversify beyond its COVID-19 vaccine success and establish itself in the competitive cancer therapeutics market.

The company, alongside its Chinese collaborator DualityBio, announced on September 5th that their investigational drug candidate, BNT323 (also known as Trastuzumab Pamirtecan), met its primary endpoint in a Phase 3 trial. The study focused on patients with HER2-positive metastatic or inoperable breast cancer, a difficult-to-treat population. An independent data monitoring committee confirmed that patients receiving the BioNTech therapy experienced a longer period without disease progression compared to those on Roche’s established standard of Read more...

de | US09075V1026 | BIONTECH’S | boerse | 68166113 |